Gout Pipeline Outlook 2025: Insights Into Therapies, Research, And Market Potential

DelveInsight's,“ Gout Pipeline Insight 2025 ” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Gout pipeline landscape. It covers the Gout pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gout pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight's comprehensive Gout Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Gout Pipeline Outlook Report

Key Takeaways from the Gout Pipeline Report

• On 28 August 2025, Crystalys Therapeutics announced a study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with hyperuricemia associated with gout.
• On 26 August 2025, Amgen conducted a study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus pegloticase Q2W with MTX, followed by a 24-week open-label extension of pegloticase Q4W with MTX, in participants with uncontrolled refractory gout.
• DelveInsight's Gout pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Gout treatment.
• The leading Gout Companies such as Jiangsu Atom Bioscience and Pharmaceutical, LG Chem, Shanton Pharma, TWi Biotechnology, Olatec Therapeutics, JW Pharmaceutical, Revive Therapeutics, Hinova Pharmaceuticals, Arthrosi Therapeutics, Dyve Biosciences, Swedish Orphan Biovitrum, Allen Pharmaceuticals, Teijin Pharma, AstraZeneca, R-Pharm, InventisBio, Sinovent, Shenyang Sunshine Pharmaceutical and others.
• Promising Gout Pipeline Therapies such as Pegloticase, Methotrexate, Epaminurad 6 mg, ABP-671, Allopurinol, D-0120, Dotinurad, Febuxostat and others.

Access DelveInsight's in-depth Gout Pipeline Analysis for a closer look at promising breakthroughs @ Gout Clinical Trials and Studies

The Gout Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Gout Pipeline Report also highlights the unmet needs with respect to Gout.

Gout Overview

Gout, historically referred to as the ""disease of kings and king of diseases,"" is one of the most common causes of chronic inflammatory arthritis, particularly in the United States. It is defined by the deposition of monosodium urate crystals in joints and surrounding tissues, driven by hyperuricemia-serum urate levels exceeding 6.8 mg/dL, the solubility threshold of urate in blood. Clinically, gout can present as acute inflammatory arthritis flares, chronic joint damage (gouty arthropathy), tophaceous deposits, uric acid kidney stones, and chronic kidney disease. Despite its long-recognized history, gout remains a well-studied and manageable condition.

Gout Emerging Drugs Profile

• LC350189: LG Chem

Tigulixostat (LC350189) is a novel xanthine oxidase inhibitor targeting the reduction of uric acid in purine metabolism, by inhibiting the activity of xanthine oxidase. It has a different structure from other xanthine oxidase inhibitors such as the purine analog xanthine oxidase inhibitor, allopurinol. Tigulixostat is under development as a first line treatment in the US and has demonstrated sufficient efficacy for sUA lowering and a good safety profile in a Phase II study. Currently, the drug is in the Phase III stage of its development for the treatment of Gout.

• SAP-001: Shanton Pharma

SAP-001 is an investigational drug developed by Shanton Pharma, specifically designed to treat refractory and tophaceous gout, a severe form of the condition that often does not respond to standard treatments. This drug functions as a urate transporter inhibitor, targeting the uric acid transporter 1 (URAT1) to lower urate levels in patients who have not adequately responded to traditional therapies like allopurinol or febuxostat. Currently, the drug is in the Phase II stage of its development for the treatment of Gout.

• D-0120: InventisBio

D-0120 is a novel oral selective uric acid transporter (URAT1) inhibitor being developed for the treatment of gout by blocking the reabsorption of uric acid (UA) within the renal proximal tubule, thereby reducing serum uric acid concentrations. As a novel URAT1 inhibitor, D-0120 is anticipated to have more potent serum UA reducing effect than the approved URAT1 inhibitor lesinurad, but with less toxicity and wider therapeutic window. The pharmacological potential of D-0120 for the treatment of hyperuricemia and gout was demonstrated in preclinical studies. The results of the in vitro hURAT1 expressed CHO cell model showed that the inhibitory activity of D-0120 is 150-fold more potent than lesinurad and slightly more potent than verinurad. A Phase I clinical trial for D-0120 has been completed in the US, and good efficacy and excellent safety profile have been observed. Currently, the drug is in the Phase II stage of its development for the treatment of Gout.

• ABP-745: Jiangsu Atom Bioscience and Pharmaceutical

ABP-745 is an emerging small molecule drug developed by Atom Bioscience, primarily targeting the treatment of acute gout. While specific mechanisms are not fully detailed, ABP-745 is noted for its anti-inflammatory properties and is designed to be orally administered. According to the company's pipeline, currently the drug is in the Phase II stage of its development for the treatment of Gout.

The Gout Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Gout with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gout Treatment.
• Gout Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Gout Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gout market

Explore groundbreaking therapies and clinical trials in the Gout Pipeline. Access DelveInsight's detailed report now! @ New Gout Drugs

Gout Companies

Jiangsu Atom Bioscience and Pharmaceutical, LG Chem, Shanton Pharma, TWi Biotechnology, Olatec Therapeutics, JW Pharmaceutical, Revive Therapeutics, Hinova Pharmaceuticals, Arthrosi Therapeutics, Dyve Biosciences, Swedish Orphan Biovitrum, Allen Pharmaceuticals, Teijin Pharma, AstraZeneca, R-Pharm, InventisBio, Sinovent, Shenyang Sunshine Pharmaceutical and others.

Gout Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical

Gout Products have been categorized under various Molecule types such as

• Protein
• Small interfering RNA
• Small molecule

Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ Gout Market Drivers and Barriers, and Future Perspectives

Scope of the Gout Pipeline Report

• Coverage- Global
• Gout Companies- Jiangsu Atom Bioscience and Pharmaceutical, LG Chem, Shanton Pharma, TWi Biotechnology, Olatec Therapeutics, JW Pharmaceutical, Revive Therapeutics, Hinova Pharmaceuticals, Arthrosi Therapeutics, Dyve Biosciences, Swedish Orphan Biovitrum, Allen Pharmaceuticals, Teijin Pharma, AstraZeneca, R-Pharm, InventisBio, Sinovent, Shenyang Sunshine Pharmaceutical and others.
• Gout Pipeline Therapies- Pegloticase, Methotrexate, Epaminurad 6 mg, ABP-671, Allopurinol, D-0120, Dotinurad, Febuxostat and others.
• Gout Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Gout Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Gout drug development? Find out in DelveInsight's exclusive Gout Pipeline Report-access it now! @ Gout Emerging Drugs and Major Companies

Table of Contents